Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative, proprietary Affimer® and pre|CISION™ platforms.
| Registrars: |
Capita Registrars |
| CEO: |
Christina Coughlin |
| Non-Executive Chairman: |
Richard Hughes |
| Non-Executive Director: |
Paul Fry, Mark Goldberg, David Bryant |
| Senior Independent Director: |
Patrick Vink |
| Address: |
Scale Space, White City, Imperial College Campus, 58 Wood Lane, London, United Kingdom |
| Phone: |
+44 (0)20 3911 0353 |
| Fax: |
+44 (0)84 4414 0453 |
| Website: |
http://avacta.com/ |
| Email: |
|